{"DataElement":{"publicId":"2183023","version":"2","preferredName":"Clinical Trial Phase Code","preferredDefinition":"Character code to specify the phase of a clinical trial. [Manually-curated].","longName":"CLIN_TRL_PHASE_CD","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2183020","version":"1","preferredName":"Protocol Phase","preferredDefinition":"Designation of phase for a clinical trial.","longName":"PROT_PHASE","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2223331","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B105A-B8AD-27F8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223291","version":"1","preferredName":"Phase","preferredDefinition":"A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","longName":"C25257","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase","conceptCode":"C25257","definition":"A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B0359-D8F5-231D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008529","version":"1","preferredName":"Research Protocols","preferredDefinition":"the identification of cancer research protocols.","longName":"RSCH_PROT","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECC2BE-2F27-348A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7F645D4-4CF3-68AD-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-04-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2183021","version":"2","preferredName":"Clinical Trial Phase Code","preferredDefinition":"Character code to specify the phase of a clinical trial. [Manually-curated].","longName":"PROT_PHASE_CD","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"I","valueDescription":"Phase I Trial","ValueMeaning":{"publicId":"2578679","version":"1","preferredName":"Phase I Trial","longName":"2578679","preferredDefinition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase I Trial","conceptCode":"C15600","definition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0064-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"TAYLORT","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC5135-ED9B-1860-E044-0003BA3F9857","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"I/II","valueDescription":"Phase I/II Trial","ValueMeaning":{"publicId":"2578680","version":"1","preferredName":"Phase I/II Trial","longName":"2578680","preferredDefinition":"A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase I/II Trial","conceptCode":"C15693","definition":"A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0065-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC5135-EDA5-1860-E044-0003BA3F9857","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"II","valueDescription":"Phase II Trial","ValueMeaning":{"publicId":"2578681","version":"1","preferredName":"Phase II Trial","longName":"2578681","preferredDefinition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase II Trial","conceptCode":"C15601","definition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0066-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"TAYLORT","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC5135-EDAF-1860-E044-0003BA3F9857","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"III","valueDescription":"Phase III Trial","ValueMeaning":{"publicId":"2578682","version":"1","preferredName":"Phase III Trial","longName":"2578682","preferredDefinition":"A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase III Trial","conceptCode":"C15602","definition":"A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0067-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC5135-EDB9-1860-E044-0003BA3F9857","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"IV","valueDescription":"Phase IV Trial","ValueMeaning":{"publicId":"2578683","version":"1","preferredName":"Phase IV Trial","longName":"2578683","preferredDefinition":"Generally, a Phase IV trial is a randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase IV Trial","conceptCode":"C15603","definition":"A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0068-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC5135-EDC3-1860-E044-0003BA3F9857","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"No phase","valueDescription":"No phase in protocol design","ValueMeaning":{"publicId":"2698169","version":"1","preferredName":"No phase in protocol design","longName":"2698169v1.00","preferredDefinition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed._No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trial Phase","conceptCode":"C48281","definition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FEC515A-65D6-1907-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC515A-65EF-1907-E044-0003BA3F9857","beginDate":"2007-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"REEVESD","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"II/III","valueDescription":"Phase II/III Trial","ValueMeaning":{"publicId":"2579213","version":"1","preferredName":"Phase II/III Trial","longName":"2579213","preferredDefinition":"A trial to study response to a new treatment and the effectiveness of the treatment compared with the standard treatment regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase II/III Trial","conceptCode":"C15694","definition":"A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-027A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FEC515A-6604-1907-E044-0003BA3F9857","beginDate":"2007-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"REEVESD","dateModified":"2007-11-27","deletedIndicator":"No"},{"value":"0","valueDescription":"Phase 0 Trial","ValueMeaning":{"publicId":"2698170","version":"1","preferredName":"Phase 0 Trial","longName":"2698170","preferredDefinition":"A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase 0 Trial","conceptCode":"C54721","definition":"A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FEC515A-6612-1907-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3E16952-D5E4-D518-E040-BB89AD437268","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-05","modifiedBy":"ONEDATA","dateModified":"2014-03-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2698168","version":"1","preferredName":"Clinical Trial Protocol Trial Phase Classification Code","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.:No Value Exists:A system of numbered categories for representation of data.","longName":"C25320:C48281:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Trial Phase","conceptCode":"C48281","definition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FEC5135-ED74-1860-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ONEDATA","dateModified":"2007-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FEC5135-ED85-1860-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":"2023.8.22 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812942","version":"1","longName":"caCTUS","context":"NCIP"},{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"}]},{"publicId":"2190530","version":"1","longName":"Demonstration Applications","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812347","version":"1","longName":"Firebird","context":"NCIP"}]},{"publicId":"2724612","version":"0.53","longName":"Clinical Trials Object Data System (CTODS)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000404","version":"1","longName":"gov.nih.nci.ctom.domain","context":"NCIP"}]}],"AlternateNames":[{"name":"ENGLISH","type":"CONTEXT NAME","context":"CCR"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"gov.nih.nci.ctom.domain.Protocol.phaseCode","type":"UML Qualified Attr","context":"NCIP"},{"name":"Protocol:phaseCode","type":"UML Class:UML Attr","context":"NCIP"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Protocol Phase","type":"Preferred Question Text","description":"Protocol Phase","url":null,"context":"CCR"},{"name":"Specify the clinical trial phase:","type":"Application Standard Question Text","description":"Specify the clinical trial phase:","url":null,"context":"NHLBI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3FEB8D7C-D1A2-1FB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"ZHANGW","dateModified":"2015-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}